Boston, MA 12/13/2013 (wallstreetpr) – The success of CytRx Corporation (NASDAQ:CYTR) latest cancer drug – Aldoxorubicin – has driven stock prices by over 50%. The drug has just proved to be more effective than the more commonly used drug doxorubicin, as Aldoxorubicin prevented growth of tumorous soft-tissue more effectively.
Chemotherapy is the most used treatment for cancer. However, Cytrx new drug has been able to prove its prowess in preventing recurrence of sarcomas as effectively, where chemotherapy itself had failed.
Aldoxorubicin Single Agent treatment
Paeans are being sung of Aldoxorubicin because it has proven to be very successful in preventing regrowth of cancerous tissue, even when used singly. Most times, the soft tissues of the cancerous cells are non-responsive to chemotherapy itself. Aldoxorubicin can now be used in treating such conditions and is the first of the drugs prescribed to treat conditions of soft tissue of sarcoma. However, there have been talks of incidence of nausea, increased mucositis as well as thrombocytopenia, for grade 3 and grade 4 besides vomiting. But the conditions were of the manageable levels and could easily resolvable.
CytRx Corporation (NASDAQ:CYTR) has grown from strength to strength over the past year, based on the success of Aldoxorubicin.
Next phase: Public Offering
The distinct growth spurt can be noted at the time of the September of 2013. Aldoxorubicin’s successful clinical trials led the run-up to the announcement of the results. Now, the company has also had a successful public opening in October last, with 10 million new shares being issued. However, there was a fall in price of the stock by 30% as a reaction to the process.
CytRx Corporation (NASDAQ:CYTR) rallied earlier this month, growing by nearly 8%, in the post-conference stage of the LD MICRO Main Event Conference in Los Angeles. The company is expected to debut more number of catalysts in the near future.
